Urol. praxi. 2026;27(2):91-93 | DOI: 10.36290/uro.2026.005

Individualization of systemic treatment for advanced prostate cancer

MUDr. Jana Katolická, Ph.D., MUDr. Lucia Tomková
Onkologicko-chirurgické oddělení FN u sv. Anny, Brno

Renal cell carcinoma (RCC) accounts for approximately 2-3 % of all malignancies, and its incidence has been steadily increasing. From the perspective of systemic therapy, immunotherapy has become a key pillar of modern RCC treatment. Over the past decade, immune checkpoint inhibitors (ICI) have emerged as an essential component of therapy for both advanced disease and localized disease at high risk of relapse. This article summarizes the role of immunotherapy in the management of metastatic RCC and its position in the adjuvant setting following surgical treatment.

Keywords: renal cell carcinoma, imunotherapy, adjuvant treatment.

Received: January 19, 2026; Accepted: February 13, 2026; Published: June 10, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Katolická J, Tomková L. Individualization of systemic treatment for advanced prostate cancer. Urol. praxi. 2026;27(2):91-93. doi: 10.36290/uro.2026.005.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 10.6.2027

    References

    1. Choueiri TK, Tomczak P, Park SH, et al. Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. N Engl J Med. 2021;385:683-694. doi: 10.1056/NEJMoa2106391. Go to original source... Go to PubMed...
    2. European Association of Urology. EAU Guidelines on Renal Cell Carcinoma. 2025.
    3. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 2025.
    4. Powles T, Albiges L, Bex A, et al. ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up of Renal Cell Carcinoma. Ann Oncol. 2023;34:295-310.
    5. Available from: www. linkos.cz. [Cited 12.2.2026].
    6. Available from: https://www.imdconline.com. [Cited 12.2.2026].
    7. Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. PMID: 29562145; PMCID: PMC5972549. Go to original source...
    8. Rini BI, Plimack ER, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16. PMID: 30779529. Go to original source... Go to PubMed...
    9. Motzer RJ, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. Lancet Oncol. 2022;23(7):888-898. doi: 10.1016/S1470-2045(22)00290-X. Go to original source... Go to PubMed...
    10. Choueiri TK, Eto M, Motzer R, et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol. 2023;24(3):228-238. doi: 10.1016/S1470-2045(23)00049-9. Go to original source... Go to PubMed...
    11. Úhradová vyhláška. Available from: https://mzd.gov.cz/wp-content/uploads/2025/11/Uhradova_vyhlaska_2026. [Cited 12.2.2026].
    12. Motzer R, Escudier B, Burotto M, et al. Nivolumab plus cabozantinib vs sunitinib for previously untreated advanced renal cell carcinoma: Final follow-up results from the CheckMate 9ER trial. 2025 ASCO Genitourinary Cancers Symposium. Abstract 439. Presented February 15, 2025. Go to original source...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.